Search Results - "BUADI, Francis"

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death by Muchtar, Eli, Gertz, Morie A., Kumar, Shaji K., Lacy, Martha Q., Dingli, David, Buadi, Francis K., Grogan, Martha, Hayman, Suzanne R., Kapoor, Prashant, Leung, Nelson, Fonder, Amie, Hobbs, Miriam, Hwa, Yi Lisa, Gonsalves, Wilson, Warsame, Rahma, Kourelis, Taxiarchis V., Russell, Stephen, Lust, John A., Lin, Yi, Go, Ronald S., Zeldenrust, Steven, Kyle, Robert A., Rajkumar, S.Vincent, Dispenzieri, Angela

“…In light of major advances in immunoglobulin light chain (AL) amyloidosis, we evaluated the trends in presentation, management, and outcome among 1551 newly…”
Get full text

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy by Russell, Stephen J., MD, PhD, Federspiel, Mark J., PhD, Peng, Kah-Whye, PhD, Tong, Caili, MS, Dingli, David, MD, PhD, Morice, William G., MD, PhD, Lowe, Val, MD, O'Connor, Michael K., PhD, Kyle, Robert A., MD, Leung, Nelson, MD, Buadi, Francis K., MD, Rajkumar, S. Vincent, MD, Gertz, Morie A., MD, Lacy, Martha Q., MD, Dispenzieri, Angela, MD

“…Abstract MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging…”
Get full text

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma by Lonial, Sagar, Jacobus, Susanna, Fonseca, Rafael, Weiss, Matthias, Kumar, Shaji, Orlowski, Robert Z, Kaufman, Jonathan L, Yacoub, Abdulraheem M, Buadi, Francis K, O'Brien, Timothy, Matous, Jeffrey V, Anderson, Daniel M, Emmons, Robert V, Mahindra, Anuj, Wagner, Lynne I, Dhodapkar, Madhav V, Rajkumar, S Vincent

“…Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression…”
Get full text

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements by KUMAR, Shaji, DISPENZIERI, Angela, GREIPP, Philip R, LUST, John A, RUSSELL, Stephen J, KYLE, RobertA, VINCENT RAJKUMAR, S, GERTZ, Morie A, LACY, Martha Q, HAYMAN, Suzanne R, BUADI, Francis K, COLBY, Colin, LAUMANN, Kristina, ZELDENRUST, Steve R, LEUNG, Nelson, DINGLI, David

“…Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and the current prognostic classification is based on cardiac biomarkers…”
Get full text

Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein by Kotchetkov, Rouslan, Susman, David, Bhutani, Divaya, Broch, Kaspar, Dispenzieri, Angela, Buadi, Francis K.

“…Sporadic late‐onset nemaline myopathy (SLONM) associated with monoclonal protein (MP) is a rare disease with an aggressive, and often fatal course. Whether…”
Get full text

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing by Kumar, Shaji K., Buadi, Francis K., Rajkumar, S. Vincent

“…The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs, which are…”
Get full text

Reply to: Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein by Kotchetkov, Rouslan, Susman, David, Bhutani, Divaya, Broch, Kaspar, Dispenzieri, Angela, Buadi, Francis K.

Get full text

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time by Sidiqi, M Hasib, Aljama, Mohammed A, Buadi, Francis K, Warsame, Rahma M, Lacy, Martha Q, Dispenzieri, Angela, Dingli, David, Gonsalves, Wilson I, Kumar, Shaji, Kapoor, Prashant, Kourelis, Taxiarchis, Hogan, William J, Gertz, Morie A

“…Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with immunoglobulin light chain (AL) amyloidosis for more than two decades. Early…”
Get full text

Improved survival in multiple myeloma and the impact of novel therapies by Kumar, Shaji K., Rajkumar, S. Vincent, Dispenzieri, Angela, Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Zeldenrust, Steven R., Dingli, David, Russell, Stephen J., Lust, John A., Greipp, Philip R., Kyle, Robert A., Gertz, Morie A.

“…Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy…”
Get full text

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 by Mikhael, Joseph R., MD, Dingli, David, MD, PhD, Roy, Vivek, MD, Reeder, Craig B., MD, Buadi, Francis K., MD, Hayman, Suzanne R., MD, Dispenzieri, Angela, MD, Fonseca, Rafael, MD, Sher, Taimur, MD, Kyle, Robert A., MD, Lin, Yi, MD, PhD, Russell, Stephen J., MD, PhD, Kumar, Shaji, MD, Bergsagel, P. Leif, MD, Zeldenrust, Steven R., MD, PhD, Leung, Nelson, MD, Drake, Matthew T., MD, PhD, Kapoor, Prashant, MD, Ansell, Stephen M., MD, PhD, Witzig, Thomas E., MD, Lust, John A., MD, PhD, Dalton, Robert J., MD, Gertz, Morie A., MD, Stewart, Keith, MBChB, Rajkumar, S. Vincent, MD, Chanan-Khan, Asher, MD, Lacy, Martha Q., MD

“…Abstract Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than 20,000 people annually in the United States. There has been a…”
Get full text

Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis by KOURELIS, Taxiarchis V, KUMAR, Shaji K, DINGLI, David, LUST, John A, YI LIN, KAPOOR, Prashant, RAJKUMAR, S. Vincent, MCCURDY, Arleigh, DISPENZIERI, Angela, GERTZ, Morie A, LACY, Martha Q, BUADI, Francis K, HAYMAN, Suzanne R, ZELDENRUST, Steven, LEUNG, Nelson, KYLE, Robert A, RUSSELL, Stephen

“…There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal…”
Get full text

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients by Stadtmauer, Edward A., Sullivan, Keith M., Marty, Francisco M., Dadwal, Sanjeet S., Papanicolaou, Genovefa A., Shea, Thomas C., Mossad, Sherif B., Andreadis, Charalambos, Young, Jo-Anne H., Buadi, Francis K., El Idrissi, Mohamed, Heineman, Thomas C., Berkowitz, Elchonon M.

“…Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2,…”
Get full text

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma by Richardson, Paul G, Kumar, Shaji K, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J, Hansson, Markus, Pour, Luděk, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W, Jackson, Sharon R, Stoppa, Anne-Marie, Gimsing, Peter, Garderet, Laurent, Touzeau, Cyrille, Buadi, Francis K, Laubach, Jacob P, Cavo, Michele, Darif, Mohamed, Labotka, Richard, Berg, Deborah, Moreau, Philippe

“…The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with…”
Get full text

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement by Gonsalves, Wilson I., Buadi, Francis K., Ailawadhi, Sikander, Bergsagel, P. Leif, Chanan Khan, Asher A., Dingli, David, Dispenzieri, Angela, Fonseca, Rafael, Hayman, Susan R., Kapoor, Prashant, Kourelis, Taxiarchis V., Lacy, Martha Q., Larsen, Jeremy T., Muchtar, Eli, Reeder, Craig B., Sher, Taimur, Stewart, A. Keith, Warsame, Rahma, Go, Ronald S., Kyle, Robert A., Leung, Nelson, Lin, Yi, Lust, John A., Russell, Stephen J., Zeldenrust, Stephen R., Fonder, Amie L., Hwa, Yi L., Hobbs, Miriam A., Mayo, Angela A., Hogan, William J., Rajkumar, S. Vincent, Kumar, Shaji K., Gertz, Morie A., Roy, Vivek

“…Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for…”
Get full text

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria by Lakshman, Arjun, Rajkumar, S. Vincent, Buadi, Francis K., Binder, Moritz, Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Dingli, David, Fonder, Amie L., Hayman, Suzanne R., Hobbs, Miriam A., Gonsalves, Wilson I., Hwa, Yi Lisa, Kapoor, Prashant, Leung, Nelson, Go, Ronald S., Lin, Yi, Kourelis, Taxiarchis V., Warsame, Rahma, Lust, John A., Russell, Stephen J., Zeldenrust, Steven R., Kyle, Robert A., Kumar, Shaji K.

“…In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) and bone marrow-plasma cell percentage (BMPC%) ≥…”
Get full text

Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma by Nandakumar, Bharat, Baffour, Francis, Abdallah, Nadine H., Kumar, Shaji K., Dispenzieri, Angela, Buadi, Francis K., Dingli, David, Lacy, Martha Q., Hayman, Suzanne R., Kapoor, Prashant, Leung, Nelson, Fonder, Amie, Hobbs, Miriam, Hwa, Yi Lisa, Muchtar, Eli, Warsame, Rahma, Kourelis, Taxiarchis V., Go, Ronald S., Kyle, Robert A., Gertz, Morie A., Rajkumar, S. Vincent, Klug, Jason, Korfiatis, Panagiotis, Gonsalves, Wilson I.

“…Background Sarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning–based segmentation…”
Get full text

Mortality trends in multiple myeloma after the introduction of novel therapies in the United States by Binder, Moritz, Nandakumar, Bharat, Rajkumar, S. Vincent, Kapoor, Prashant, Buadi, Francis K., Dingli, David, Lacy, Martha Q., Gertz, Morie A., Hayman, Suzanne R., Leung, Nelson, Fonder, Amie, Hobbs, Miriam, Hwa, Yi Lisa, Muchtar, Eli, Warsame, Rahma, Kourelis, Taxiarchis V., Gonsalves, Wilson I., Russell, Stephen, Lin, Yi, Siddiqui, Mustaqeem, Kyle, Robert A., Dispenzieri, Angela, Kumar, Shaji K.

“…Advances in the understanding of disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma. Given that these…”
Get full text

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines by Kumar, Shaji K., MD, Mikhael, Joseph R., MD, Buadi, Francis K., MD, Dingli, David, MD, PhD, Dispenzieri, Angela, MD, Fonseca, Rafael, MD, Gertz, Morie A., MD, Greipp, Philip R., MD, Hayman, Suzanne R., MD, Kyle, Robert A., MD, Lacy, Martha Q., MD, Lust, John A., MD, PhD, Reeder, Craig B., MD, Roy, Vivek, MD, Russell, Stephen J., MD, PhD, Short, Kristen E. Detweiler, RN, CNP, Stewart, A. Keith, MD, Witzig, Thomas E., MD, Zeldenrust, Steven R., MD, PhD, Dalton, Robert J., MD, Rajkumar, S. Vincent, MD, Bergsagel, P. Leif, MD

“…Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is…”
Get full text

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing by Muchtar, Eli, Gertz, Morie A., Kyle, Robert A., Lacy, Martha Q., Dingli, David, Leung, Nelson, Buadi, Francis K., Hayman, Suzanne R., Kapoor, Prashant, Hwa, Yi Lisa, Fonder, Amie, Hobbs, Miriam, Gonsalves, Wilson, Kourelis, Taxiarchis V., Warsame, Rahma, Russell, Stephen, Lust, John A., Lin, Yi, Go, Ronald S., Zeldenrust, Steven, Rajkumar, S. Vincent, Kumar, Shaji K., Dispenzieri, Angela

“…To describe the clinical and laboratory characteristics of patients with meticulously typed light chain (AL) amyloidosis. Patients (N=592) with biopsy-proven,…”
Get full text

What do I need to know about immunoglobulin light chain (AL) amyloidosis? by Dispenzieri, Angela, Gertz, Morie A, Buadi, Francis

“…Abstract Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive,…”
Get full text